Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088465
Status:
COMPLETED
Last Update Posted:
2012-01-11
First Post:
2004-07-26
Brief Title:
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a long-term open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot
Key objectives of the study are to
Determine how well intramuscular IM olanzapine depot works during long-term treatment
Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment
Determine the blood levels of IM olanzapine depot in patients during long-term treatment
Key objectives of the study are to
Determine how well intramuscular IM olanzapine depot works during long-term treatment
Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment
Determine the blood levels of IM olanzapine depot in patients during long-term treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1D-MC-HGKB | OTHER | Eli Lilly and Company | None |